Clinical Trials | October 23, 2025
Pimicotinib delivers lasting tumor responses and sustained symptom relief in TGCT patients
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
These findings follow positive Phase 3 results presented earlier this year
Acquisition strengthens EY’s Veeva Centers of Excellence, expanding clinical, regulatory, and commercial services for global pharma and biotech companies
The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants
First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing
Through this acquisition Merck has added Ohtuvayre (ensifentrine) to its growing cardio-pulmonary pipeline and portfolio
Subscribe To Our Newsletter & Stay Updated
